Core Viewpoint - Qizheng Tibetan Medicine (002287) reported its 2025 performance, showing a revenue of 2.416 billion yuan, representing a year-on-year growth of 3.34%, and a net profit attributable to shareholders of 646 million yuan, reflecting a year-on-year increase of 10.98% [1] Financial Performance - The company achieved an operating income of 2.416 billion yuan in 2025, which is a 3.34% increase compared to the previous year [1] - The net profit attributable to shareholders reached 646 million yuan, marking a 10.98% growth year-on-year [1]

值得一提的是，近日，奇正藏药旗下澳门全资子公司取得澳门特别行政区政府药物监督管理局核准签发 的《中成药注册证明书》，公司经典藏药催汤颗粒完成澳门注册。此次获批类别为非处方中成药 （OTC），意味着该药品可通过澳门零售药店等渠道直接触达消费者，快速适配当地民生健康需求。 公告显示，催汤颗粒处方系藏族验方，始载于公元15世纪著名藏医药学家宿喀·娘尼多吉所著的《医学 千万舍利》，为呼吸系统领域感冒类用药。 转自：中国证券报·中证网 中证报中证网讯（记者 吴科任）2月13日晚，奇正藏药发布的2025年度业绩快报显示，报告期内，公司 实现营业总收入24.16亿元，同比增长3.34%；归母净利润为6.46亿元，同比增长10.98%；扣非净利润为 4.77亿元，同比增长12.03%。 奇正藏药主营业务为藏药的研发、生产及销售，包括外用止痛药物和口服藏成药、中药等。公司表示， 2025年扣非净利润的增长主要源于营业总收入的增长。 ...

Group 1 - RuiLian New Materials reported a total operating revenue of 1.677 billion yuan for 2025, an increase of 14.95% year-on-year, with a net profit of 311 million yuan, up 23.48% year-on-year [1] - China Shenhua's subsidiary, Guoneng Qingyuan Power, successfully put its fourth generator unit into commercial operation, expected to provide approximately 20 billion kWh of clean energy annually [2] - Qijiang Airlines announced a 6.04% year-on-year decline in passenger turnover for January 2026, with a passenger load factor of 84.03%, up 1.61% year-on-year [3] Group 2 - QiZheng Tibetan Medicine reported a total operating revenue of 2.416 billion yuan for 2025, a year-on-year increase of 3.34%, with a net profit of 646 million yuan, up 10.98% year-on-year [5] - QiaoYin Co. announced the termination of its artificial intelligence industry headquarters project due to changes in investment cooperation conditions [6] - New Point Software plans to use 90.81 million yuan of surplus raised funds for new projects, including AI-driven software development [7] Group 3 - High Measurement Co. announced plans for major shareholders and executives to reduce their holdings by up to 3.19% of the company's shares [8] - SAIC Group's subsidiary plans to establish a private equity fund with an initial scale of 2.5 billion yuan, focusing on solid-state batteries and chip localization [9] - Tianqi Lithium announced the resignation of its deputy general manager due to personal career planning [10] Group 4 - ZhongKong Technology reported a total operating revenue of 8.051 billion yuan for 2025, a decrease of 11.90%, with a net profit of 450 million yuan, down 59.70% year-on-year [11] - Spring Airlines reported a 6.28% year-on-year increase in total passenger volume for January 2026, with a total available ton-kilometers of 57,008.37 [12] - Qifan Cable's controlling shareholder reduced its stake by 3% through various trading methods [13] Group 5 - China Chemical signed contracts worth a total of 36.925 billion yuan in January 2026, with significant contracts exceeding 5 billion yuan totaling 11.371 billion yuan [19] - SaiTuo Bio received a CEP certificate for its raw material drug Betamethasone, which is used to treat allergies and autoimmune inflammation [20] - Giant Star Agriculture reported a sales revenue of 649 million yuan from commodity fat pigs in January 2026, with a sales volume of 404,400 pigs [23] Group 6 - Qinglong Pipe Industry's subsidiary won a 146 million yuan pipeline project [24] - Changshan Pharmaceutical announced that some of its products are expected to be selected for national centralized procurement [26] - Yangdian Technology completed the transfer of 12.96% of its shares through an agreement [27] Group 7 - Deepin Technology's investment fund introduced new limited partners and adjusted the capital contributions of some partners [28] - Qingyun Technology plans to pledge 25% of its shares for a loan application of up to 30 million yuan [29] - LaiMei Pharmaceutical reported a 57.20% year-on-year decline in net profit for 2025 [30] Group 8 - YouLiDe reported a 16.88% year-on-year decline in net profit for 2025, with total operating revenue of 1.221 billion yuan, up 7.99% [31] - Warner Pharmaceutical reported a net profit of 241 million yuan for 2025, an increase of 46.95% year-on-year [32] - LianRui New Materials reported a net profit of 293 million yuan for 2025, an increase of 16.42% year-on-year [33] Group 9 - HuaQin Technology expects a 24.28% year-on-year decrease in net profit for 2025, with projected revenue of 1.251 billion yuan, up 9.83% [34] - QiPai Technology's shareholder subscribed for 6.3 million shares, accounting for 5.49% of the total share capital [35] - Qilin Security's shareholders completed their planned share reductions without exceeding the original plan [36] Group 10 - Dameng Data announced the lifting of the detention of its senior vice president, allowing him to resume his duties [37] - Haiyou Engineering won a contract for the "NFPS COMP5" project worth approximately 4 billion USD, with the company's share exceeding 800 million USD [38] - Yatai Group plans to sell 20.81% of its shares in Northeast Securities, pending confirmation of financial statements [39]

Group 1 - The company, Qizheng Tibetan Medicine, announced that it expects to achieve an operating revenue of 2,416.01 million yuan in 2025, representing a year-on-year growth of 3.34% [2] - The net profit attributable to shareholders of the listed company is projected to be 646.23 million yuan, reflecting a year-on-year increase of 10.98% [2]

（文章来源：证券日报） 证券日报网讯 2月13日，奇正藏药在互动平台回答投资者提问时表示，截至2026年2月10日，公司股东 总人数为32979户。 ...

奇正藏药（002287）(002287.SZ)发布2025年度业绩快报，报告期内，公司实现营业总收入24.16亿元， 较上年同期增长3.34%。实现归属于上市公司股东的净利润6.46亿元，同比增长10.98%。 ...

Core Viewpoint - Qizheng Tibetan Medicine (002287.SZ) reported its 2025 annual performance, showing a total operating revenue of 2.416 billion yuan, an increase of 3.34% compared to the same period last year, and a net profit attributable to shareholders of the listed company of 646 million yuan, representing a year-on-year growth of 10.98% [1] Financial Performance - The company achieved total operating revenue of 2.416 billion yuan [1] - The year-on-year growth in total operating revenue was 3.34% [1] - The net profit attributable to shareholders reached 646 million yuan [1] - The net profit saw a year-on-year increase of 10.98% [1]

格隆汇2月13日丨奇正藏药(002287.SZ)公布2025年度业绩快报，报告期内，公司实现营业总收入24.16亿 元，较上年同期增长3.34%，归属于上市公司股东的净利润6.46亿元，同比增长10.98%，扣除非经常性 损益后的归属于上市公司股东的净利润4.77亿元，同比增长12.03%。 ...

证券代码：002287 证券简称：奇正藏药 公告编号：2026-006 西藏奇正藏药股份有限公司 2025 年度业绩快报 二、经营业绩和财务状况情况说明 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或 重大遗漏。 特别提示： 本公告所载 2025 年度的财务数据仅为初步核算数据，已经西藏奇正藏药股份有限公司（以下简称 "公司"）内部审计部门审计，未经会计师事务所审计，与年度报告中披露的最终数据可能存在差异， 请投资者注意投资风险。 一、2025 年度主要财务数据和指标 单位：万元 | 项目 | 本报告期 | 上年同期 | 增减变动幅度（%） | | --- | --- | --- | --- | | 营业总收入 | 241,601.23 | 233,796.97 | 3.34% | | 营业利润 | 76,295.29 | 65,702.5 | 16.12% | | 利润总额 | 73,416.8 | 64,624.42 | 13.61% | | 归属于上市公司股东的净利润 | 64,623.11 | 58,228.11 | 10.98% | | 扣除非经常性损益后的归属 ...

经济观察网 奇正藏药（002287）经典藏药催汤颗粒获澳门中成药注册批准，成为澳门首个获批的藏药 品种，标志着其国际化战略迈出关键一步。同时，公司另一呼吸领域产品获批中药保护品种，强化了在 该领域的布局。 近7天，奇正藏药股价区间涨跌幅为2.47%，区间振幅达7.09%。截至最新收盘，股价报24.43元，单日下 跌1.61%。技术面显示，当前股价接近布林带中轨，存在一定压力与支撑。 机构观点 中邮证券发布报告指出，近期发布的《中药工业高质量发展实施方案》明确支持中药工业龙头企业发展 并强调发掘民族药资源，奇正藏药作为代表企业被列为受益标的。机构预测公司未来两年净利润将保持 增长。 股票近期走势 ...